

CLAIMS

1. A drug conjugate comprising a targeting moiety, a linker moiety, and a drug moiety, wherein the drug moiety is conjugated to the linker which is conjugated to the targeting moiety, and wherein the linker moiety has the structural formula (I^A) or (II^A):



or



(I^A) (II^A)


wherein:


each R is independently selected from N, CH, or C;


R' is CH or C; and


W is selected from:





,



,



,



,



,


,


,


,



,



, and


,

or a pharmaceutically acceptable salt thereof.

2. The drug conjugate of claim 1, wherein the linker has the structural formula (I^B) or (II^B):




or


.


(I^B) (II^B)

3. The drug conjugate of claim 1 or 2, wherein the linker has the structural formula (I^C):




(I^C)

4. The drug conjugate of any one of claims 1-3, wherein the linker comprises a spacer moiety and has the structural formula (III^A) or (IV^A):90989977



, or

(III^A)




,

(IV^A)


wherein X_b is the spacer moiety.

5. The drug conjugate of claim 4, wherein the spacer moiety is selected from the group consisting of an alkyl, a heteroalkyl, polyethylene glycol (PEG), and a peptide.

6. The drug conjugate of any one of claims 1-5, wherein the linker comprises a spacer moiety and a polypeptide moiety and has the structural formula (V^A) or (VI^A):



(V^A), or



,


(VI^A)

wherein Y_b is the polypeptide moiety.

7. The drug conjugate of claim 6, wherein the polypeptide moiety comprises 1 to 6 amino acids.


8. The drug conjugate of claim 7, wherein the amino acids are natural and/or unnatural amino acids.

9. The drug conjugate of any one of claims 1-8, wherein the linker comprises a spacer moiety, a polypeptide moiety, and a self-immolative moiety and has the structural formula (VII^A) or ($VIII^A$):



or

(VII^A)




,


($VIII^A$)

wherein Z_b is the self-immolative moiety.


10. The drug conjugate of claim 9, wherein the self-immolative moiety is selected from the group consisting of:




,



,




, and




.


11. The drug conjugate of any one of claims 1-10, wherein the linker is selected from the group consisting of:




,




,




,




,






,



,



,



and .



12. The drug conjugate of any one of claims 1-11, wherein

the drug moiety is a chemical agent selected from the group consisting of an antibiotic, an anti-cancer agent, a steroid, a TLR7/TLR9 antagonist, a polypeptide, a protein, and a nucleic acid;

the targeting moiety is selected from the group consisting of an antibody, small molecule, a peptide, a polypeptide, and a nucleic acid; and/or



the drug conjugate has a targeting moiety to drug moiety ratio of about 1:1 to about 1:16.

13. The drug conjugate of any one of claims 1-12, wherein W is:


or .

14. A pharmaceutical composition comprising a drug conjugate of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, carrier or diluent.

15. A compound useful for forming a linker-drug conjugate, a targeting-linker conjugate, or a targeting moiety-linker-drug conjugate, the compound having a structure comprising formula (I) or (II):


or 

(I) (II)


wherein:

A is Br or Cl;


each R is independently selected from N, CH, or C;

R’ is CH or C; and

W is selected from:



16. A compound useful for forming a conjugate of targeting moiety-linker-drug, the compound having a structure comprising formula (I) or (II):



(I) or (II)


wherein:


A is Br or Cl;

each R is independently selected from N, CH, or C;

R' is CH or C; and


W is selected from:





wherein W is covalently linked to a drug moiety, optionally via one or more spacer or linking moieties.

17. A compound useful for forming a conjugate of targeting moiety-linker-drug, the compound having a structure comprising formula (I^a) or (II^a):



(I^a) (II^a)


wherein:

A' is conjugated to or comprises a targeting moiety;

each R is independently selected from N, CH, or C;

R' is CH or C; and


W is selected from:





18. Use of a drug conjugate of any one of claims 1-13 for the manufacturing of a medicament for the therapeutic treatment of a disease or condition selected from cancer, autoimmune disorder, and infectious disease.


19. The use of claim 18, wherein the condition is one or more of cancer, an autoimmune disorder, or an infectious disease.


20. A compound selected from the group consisting of:



























, and


O
OH
N
Cl
N
.